

JOURNAL ARTICLE

SUN-309 Cytokine Signaling by Thyronine and NAD in Colon and Pancreas - Case reports Highlighting Stem Cell Differentiation and Insulin Regulation

Timothy Bilash, MD MS FACOG

Journal of the Endocrine Society, Volume 9, Issue Supplement_1, October-November 2025, bvaf149.2510, <https://doi.org/10.1210/jendso/bvaf149.2510>

Published: 22 October 2025

Abstract

Disclosure: T. Bilash: None.

There has been an explosion of interest in Thyroid dysfunction since the chemiluminescent free hormone assays, advanced imaging and biophysical techniques (Phasor FLIM) have evolved over the last 15 years. Research now identifies peripheral metabolism as intimate to Thyroid Physiology, adding cellular (non-genomic/cytoplasmic) to well studied nuclear (genomic) processes. Carrier proteins, Enzyme Converters (Deiodinase), and Trans-membrane Transport Proteins create a complex web communicating across distinct Thyroid compartments. Feedback, conversion, local accommodation among and inside cells results in precise control. There is currently not one Thyroid test accurate enough to define Thyroid Status, although Thyroid Stimulating Hormone (TSH), Thyroxine (T4 - Total and Free), and Triiodothyronine (T3 - Total and Free) are shown to be clinically determinant in function. This work reports case studies for two patients with distinct, serious medical issues in the presence of Hypothyroxinemia: Diabetes Mellitus in a Pregnant female treated with Levothyroxine, and Advanced Stage Adenocarcinoma of the Colon in a male treated with Levothyroxine and Liothyronine, leading to successful clinical outcomes. T4 vs T3 and NAD vs NADP impact sources of cellular energy; in gradient for Colon

stem cell differentiation (Wnt/b-catenin/PDK-1/NF- κ B/STAT3) and for Insulin production in Pancreatic Beta Cells (MAPK/ERK). Support for the Serum FreeT3/FreeT4 Ratio as an important clinical parameter is offered. References 1 Kira T. Pate et al., *Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer*, The EMBO Journal 2014, Vol 33, No 13, 1454-1473 (doi/10.15252/emj.201488598) 2 Maria Virginia Giolito, Michelina Plateroti, *Thyroid hormone signaling in the intestinal stem cells and their niche*, Cell Mol Life Sci 2022 Aug 10;79(9):476 (doi/10.1007/s00018-022-04503-y) 3 T. Oda et al., *Positive association of free triiodothyronine with pancreatic β -cell function in people with prediabetes*, Diabetic Medicine 2014, Vol 32, Issue 2, p. 213-219 2014 (doi.org/10.1111/dme.12589) 4 Xing Zaou et al., *Thyroid hormone can increase estrogen-mediated transcription from a consensus estrogen response element in neuroblasoma cells*, Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4890-5. (doi/10.1073/pnas.0501042102)

Presentation: Sunday, July 13, 2025

Issue Section: [Abstract](#) > [Tumor Biology](#)

Collection: [Endocrine Society Journals](#)



This content is only available as a PDF.

© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-

NoDerivs licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.



Certificate of Presentation

The Endocrine Society certifies that

Dr. Timothy Bilash

presented the following abstract at the Annual Meeting of the Endocrine Society – ENDO 2025, which was held at the Moscone Convention Center in San Francisco, California, July 12 - 15, 2025.

#5128 Cytokine Signaling by Thyronine and NAD in Colon and Pancreas
- Case reports Highlighting Stem Cell Differentiation and Insulin Regulation

A handwritten signature in black ink that reads "Janel Johnson".

Janel Johnson
Director, Event Education Design
Endocrine Society

II. Patient Case1 - Diabetes Mellitus in Pregnancy

The Patient is a 28 y/o pregnant female followed in her first pregnancy since the first trimester. She presented to the Hospital in Preterm Labor with Acute

Case 1
21 y/o first pregnancy
29 wk Preterm Labor, Pyelopnehritis
Eating disorder
Depression in Therapy
TOB 1/2 PPD
Milk Protein allergy
Renal CT neg
Peripheral Glucose 226 post prandial, normal fasting
UTI Recurrent Treated @28 weeks
Bacterial Vaginosis Treated
H/O high grade Pap Treated, Repeat negative
Placed on 2300 cal ADA Diet
Required Insulin 25 units/day, tapered off at 1 wk
Placed on Levothyroxine 50 mcg daily
1 hr glucola @30 weeks on L-thyroxine 136 (Fasting 80)
Fetal Dilated Renal Ureters - NI @Birth

Pyelonephritis at 28 weeks. She was placed on Insulin and Thyroxine for elevated blood sugars over 200, with Laboratory and Clinical evidence of Hypothyroxinemia (sub-normal Free T4). She responded well, continued on Levothyroxine with one increase in dose, then weaned from Insulin advancing to vaginal delivery at term without incident. A Fetal Hydronephrosis noted prenatally resolved at birth.

	TSH	FREE T4	Free T3	TOT T4	TBG	Urinary Iodide	TGab	TRAB	Glucose	2 hr Glucola
Lab NL Range	0.49-4.67 4.18	0.71-1.85 1.04	2.3-4.2 1.9	4.5-12.0 7.5	13-39				90-105	<135
29 weeks 0 LT4	0.51 0% nl	0.76 5% nl	2.8 5% nl	11.8 97%		Decreased			226 Hi	
30 weeks (on LT4 50)	0.79 7% nl	0.8 9% nl			50 Hi		0	0		136

III. Patient Case2 - Adenocarcinoma of the Colon Stage 3/4

The Patient is a 60 y/o male diagnosed at surgery for a ruptured viscus with a Stage 3 Adenocarcinoma in the left descending Colon. At the time of surgery he was on Levothyroxine and Triiodothyronine for Hypothyroxinemia with otherwise stable Thyroid symptoms. A single 2 cm moderately differentiated tumor was removed at successful segmental resection (colostomy revised 9 months later), with 1/13 adjoining lymph nodes 95% replaced with moderately differentiated Adenocarcinoma of the Colon. Later revisit found B-Cell Lymphoma in all 13 nodes. Patient declined Intravenous Chemotherapy for the Stage 3 Carcinoma, noting complete resection and clear surgical margins. Oral Capecitabine therapy was offered, then discontinued after 2 months secondary to foot-hand syndrome. Adjuvant Curcumin as Turmeric and Epigallocatechin-3 gallate (EGG) supplementation was continued for 6 months. Pre-diagnosis Thyroid replacement dose for Hypothyroxinemia was adjusted, decreasing

Levothyroxine T4 which is demonstrated to stimulate solid tumor growth, and increasing Triiodothyronine known to differentiate Colon Stem Cells. Pre-diagnosis Vitamin D3 supplementation was also augmented.

Subsequent MRI and PET-CT imaging at 9 months identified two, isolated adjacent 2&3 cm lesions in the Left Lobe of the Liver, c/w Stage 4 metastatic tumor, and little change over 9 months on comparison with non-contrast imaging. Resection of the Left Lobe of the liver and Cholecystectomy was performed at 1 year post diagnosis.

Additional Follicular Cell Lymphoma in multiple locations was identified at 9 months (Collision Tumor). At 2 years a Retroperitoneal 4-cm ParaCaval Lymph Node was removed robotically (B-cell Lymphoma CD10 POS (64%), CD19, CD20, CD10, lamda light chain, CD23, CD38) and Biopsy of a ParaProstate Nodule indicated Hybrid Schwannoma.

Colonoscopy at 3 years resected a 0.8cm Transverse Colon Tubular Adenoma Polyp, and at 5 years a 0.3 cm Cecal Adenoma. Repeat Pet scan at 5 years showed no Colon tumor residual or metastasis and stable imaging. Patient is doing well ten years post diagnosis.


IV. INTRODUCTION

Peripheral metabolism and local control with feedback loops are demonstrated in Thyroid Physiology. Free hormone assays are now available. Carrier proteins, Enzyme Iodinase and Trans-membrane Transporters identify feedback and fine controls. Thyroxine (T4 - Total and Free), TSH, and now Triiodothyronine (T3 - Total and Free) are clinically useful. This work introduces some of the common pathways involved in Colon Cancer and Diabetes Mellitus.

V. Thyroid Hormone Physiology

THs are transported to distal organs carried on serum proteins such as Thyroid Binding protein (TBP), Transthyretin (Pre-Albumin) and Albumin. At the cells, transmembrane transporters (MCT, OATP, and LAT) facilitate the entry of TH into cells, which follow the gradient of free hormone between the extracellular fluid and cytoplasm. T₄ and (T₃ from T₄) bind to intracellular receptors; TR α and TR β initiate nuclear TH signaling, regulating target genes and metabolic pathways (genomic). Local (peripheral) mechanisms dominate and compartmentalise hormonal control thru non-genomic actions.

VI. INTESTINAL CELL WALL RENEWAL



Intestinal epithelium demonstrate a proliferation zone for Stem Cell activity and Progenitor proliferation at the base (crypts). A differentiation zone defines the region where Progenitors enter and differentiate while migrating toward the top of the vertical axis. Differentiated cells reside at the lumen and finally die by apoptosis and are shed into the lumen.

*Adapted from Optimal Thyroid Hormone Replacement,
Jacqueline Jonklaas, Endocr Rev. 2021 Sep 20;43(2):366–404*

VII. THYROID HORMONES

Thyroxine- T4 binds to cell membrane Integrin $\alpha v \beta 3$, proliferating cancer cells; in colon adenocarcinoma cell lines T4 increases AMPK and inhibits mTOR resulting in increased tumor progression by interfering with anti-tumor immune responses, activating PD-L1 thru the ERK1/2 pathway; induces serine phosphorylation of ER α . These T4 pro-mitogenic effects are in sharp contrast to intracellular T3.

Triiodothyronine- The biological activity of T3 is largely determined by its intracellular concentration. T3 promotes cell growth and differentiation; enhances glycolysis to Pyruvate in the Cytosol; increases OXPHOS; induces Mitochondrial Calcium uptake & Mitochondrial Dehydrogenase; induces differentiation of Stem Cells towards secretory lineages and reduces proliferation in colon cancer cells; improves mitochondrial health, cristae structure & membrane potential; activates tumor-suppressive E-cadherin, triggering plasma-membrane localization of Beta-catenin, which prevents its solubilization and nuclear transit; suppresses cyclin-CDK complexes,

effecting G1 cell cycle arrest and downregulation of cyclins D1 and E.

Thyroid Stimulating Hormone -TSH stimulates NAD⁺ Kinase, increases reoxidation of NADP from NADPH ; TSH stimulates peroxisome activity.

Binding Proteins- THs are transported to distal organs bound to serum proteins. Most hormone is bound and inactive: Thyroid Binding protein (TBP), Transthyretin (PreAlbumin), Albumin; Vitamin D Binding Protein (VDBP), Retinol Binding Protein (RBP) also transport.

Effector Proteins- Important effector proteins are Beta-catenin which functions as membrane bound in complex with E-Cadherin in a zinc finger complex. Soluble nuclear beta catenin stimulates solid tumor cancers; SIRT1 induces NAD⁺ mediated gene repression. T3 inhibits mTOR, important for intestinal regeneration and preservation of “reserve SCs” from DNA damage.

Central and Peripheral Deiodinase Enzymes- DIO1 and DIO2 activate, converting intracellular T4 to T3. DIO3 (T3>T2 and T3>rT3) is inactivate.

VIII. THYROID HORMONE GENOMIC AND NON-GENOMIC RECEPTORS

Genomic Thyroid Receptors (TR) are mainly located in the nucleus. In the absence of Thyroid binding, TR act as repressors: TR α 1 in the undifferentiated crypt compartment in Stem Cells (SC), modulating the expression of cell division and cell cycle regulators through Wnt and Notch; binding T4. TR β 1 is downregulated in CRC mucosa, and its overexpression inhibits proliferation and migration.

Retinoid X Receptors (RXRs) form heterodimers with other nuclear receptors like [RAR](#), [PPAR](#), [VDR](#), and [TR](#). RXR binds T3 with high affinity to mediate feedback regulation, which may have a stronger effect than nutrient composition.

Some TH target genes fall under epigenomic regulation, which modifies their transcription; Sirtuin-mediated regulate the metabolic state of intestinal SCs far away (centrally) from as well as in the niche (locally).

IX. NON-GENOMIC THYROID RECEPTORS

Integrin $\alpha\beta3$ is embedded in the cell membrane exposed to the outside of the cell and cytoplasmic interior; in plasma membranes (T4), in cytoplasmic membranes (T3), in mitochondrial membranes (T3). Integrins play a crucial role in cell adhesion by binding to extracellular matrix (ECM) proteins as a sensor for the ECM. S1 subunit binding by T3 leads to PI3K/Akt pathway activation; S2 subunit binding by T4 activates both PI3K/Akt and MAPK.

Non-genomic actions are dependent on nuclear uptake of T3 and T3–TR complexes with other nucleoproteins: MAPKs, PKC, AKT, and PI3-K-AKT. Crypt-base columnar cells (CBCs) are considered the active Stem Cells of the intestinal epithelium. NRF-1, NRF-2, (PPAR) γ are intermediate factors; coactivators (PGC)-1 α and PGC-1 β are downstream.

X. THYROID HORMONE SIGNALING AND REGULATION


Thyroid Hormones participate in multiple reactions: Proliferation/Division, Differentiation, Migration, Invasion, Growth. Interplay occurs between classical cell signaling (coordinating modification) and metabolic pathways

(energy) utilizing the mitochondria in Stem Cell maintenance/ differentiation.

XI. MICROENVIRONMENT AROUND THE CELL

There is concentration and activity gradients of along the Colon villus axis. TR α 1, Wnt, Notch decrease towards the villi; while BMP, Hedgehog, and Triiodothyronine (T3) increase. These non-nuclear signaling pathways balance cell proliferation and cell differentiation. Crosstalk between the epithelium and the underlying mesenchyme is absolutely required for intestinal maturation and stem cell emergence.

DIO3 is expressed at the base of the crypts, and decreases towards the tip of the villus: it is maximally expressed in proliferating cells lowering T3, and decreasing with differentiation. T3 is a differentiating agent: in CaCo-2 cells, external T3 reduces growth rate and Cyclin D1, a marker for the G1-S phase transition (Dentice et al 2012).



NOTCH


Notch signaling is a critical regulator of the tumor microenvironment, influencing various cellular and molecular processes that contribute to cancer progression, metastasis, and drug resistance.

XII. OXPHOS NADH PRODUCTION AND THE MITOCHONDRIAL INNER MEMBRANE PROTON GRADIENT


Active Stem Cells rely highly upon Oxidative Phosphorylation (OXPHOS), in “blocks” of reactions within the Mitochondria Membrane:

- 1) Oxidation of substrates generates Hydrogen Ion H^+ gradients that couples with the ETC.
- 2) Dissipating Hydrogen Ion H^+ gradients for synthesis exports ATP (ATP Synthase and Adenosine Nucleotide Translocase ANT, into the cytoplasm.
- 4) Phosphorylation reactions provide the Energy for this.

Proton Gradients in Mitochondria- "The Electron Transport Chain generates ATP and NADH through proton flux across the membrane, though this process is not fully coupled to ATP synthesis." A “proton leak” dissipates part the energy of the H^+ gradient as heat, balancing the redox pumps generating the gradient. Hyperthyroidism increases electron flow through the respiratory chain, modulated by genomic and non-genomic actions of TH.



(Adapted from Luengo et al NCI Jan 13, 2021
<https://frederick.cancer.gov/news/new-clarity-warburg-effect>)




(Adapted from https://en.wikipedia.org/wiki/Oxidative_phosphorylation)


Energy production in the cell can involve direct oxidation of Glucose to Pyruvate in the Cytosol (Glycolysis); with the additional step of Fermentation to Lactate or Oxidation to Pyruvate for NADH in the Cytosol and ATP or NADH in the Mitochondria. Oxidative Phosphorylation described in the

Lunego and Wiki articles diagrammed above identify the distinct parts. TCA itself does not require Oxygen, but needs to dispose of its products to continue producing energy.

NAD/NADH/NADPH



(adapted from Schaefer et al (2018) NADH
NADH Autofluorescence - A Marker on its Way)
<https://onlinelibrary.wiley.com/doi/full/10.1002/cyto.a.23597>



(adapted from Ju, Lin, Tian, Xie, Xu (2020) NADPH homeostasis
in Cancer <https://www.nature.com/articles/s41392-020-00326-0>)

The above from Schaefer et al and Ju et al introduce newer concepts in Energy Metabolism for Cancer Cells. Substances such as Lactate and NAD are shared among cell compartments and nearby/distant cells to produce the high energy needed for cell reproduction. Thus Cancer cells pirate it's fuel from nearby cells and muscle in particular which can process using oxygen.

XIV. BLOOD SUGAR

TR α -T3 binding impairs glucose-stimulated insulin secretion by acting directly at the level of the pancreatic islets. TH cell-signaling induces carbohydrate response element-binding protein (ChREBP), stimulating glycolysis and lipogenesis (production of energy compounds) in response to low glucose and insulin in a TR α - and TR β - dependent manner; reduced insulin levels stimulates ChREBP expression which in turn influences glucose response and insulin secretion.

Triiodothyronine (T3) increases hepatic glucose production, stimulates glucose uptake in peripheral tissues (GLUT4 in skeletal muscle) and SGLT1 (in intestine) that slows down the movement of food increasing nutrient and

water absorption). This increases GLP-1 and insulin secretion, ultimately leads to a net decrease in blood glucose levels.

A recent study found that free triiodothyronine (FT3) concentration was inversely associated with microangiopathic complications and metabolic control in euthyroid patients with type 1 diabetes mellitus (T1DM). After adjusting for confounding factors, Zhang et al found in their study that serum FT3 was inverse to HbA1c.

XV. COLON CANCER

T3 and TR α 1 (T4) control the metabolic state of SCs and regulate their self-renewal capacity.

Depletion of DIO3 in adenocarcinoma downregulating Wnt is pro-differentiation. High T3 stimulates excess ROS in a stressed cell, yet normal surrounding microenvironment would function normally and absorb the High T3 effects. T3 promotes cell growth (increased size) and differentiation (complete the mesenchymal transition). Colon cancer actions of TH are mainly mediated through Serum T4, promoting cell proliferation/division at the membrane receptor $\alpha v \beta 3$. T4 binding favors an increase of AMPK and the inhibition of mTOR resulting in increased tumor cell aggressivity.

XVI. Free T3/ FreeT4 Ratio

Table 2. Coefficients of linear fit: $y = Ax + B$ among the variables \log_e of TSH (mIU/L), FT3 (pmol/L) and FT4 (pmol/L) in euthyroidism, hypothyroidism and hyperthyroidism. The included errors are standard errors in slope and intercept, and the P-value for F-test is obtained from the linear regression analysis

Thyroid status	Values	$\ln(TSH)$ vs FT4	$\ln(TSH)$ vs FT3	FT3 vs FT4
<u>Euthyroidism</u> (N = 2413)	Slope (A)	-0.02±0.003	-0.02±0.01	0.03±0.006
	Intercept (B)	0.99±0.05	0.84±0.06	5.00±0.08
	Pearson's r	-0.11	-0.03	0.11
	P-value	<0.001	0.07	<0.001
<u>Subclinical hypothyroidism</u> (N = 649)	Slope (A)	-0.005±0.004	-0.04±0.02	0.06±0.01 †
	Intercept (B)	2.02±0.06	2.16±0.08	4.56±0.15
	Pearson's r	-0.04	-0.10	0.21
	P-value	0.26	0.013	<0.001
<u>Overt hypothyroidism</u> (N = 113)	Slope (A)	-0.23±0.02	-0.56±0.09	0.18±0.02 ††
	Intercept (B)	4.84±0.11	5.40±0.29	2.17±0.12
	Pearson's r	-0.75	-0.51	0.66
	P-value	<0.001	0.06	<0.001
<u>Subclinical hyperthyroidism</u> (N = 175)	Slope (A)	-0.05±0.02	-0.46±0.08	0.03±0.02
	Intercept (B)	-1.79±0.46	0.21±0.52	5.53±0.38
	Pearson's r	-0.13	-0.38	0.10
	P-value	0.07	<0.001	0.17
<u>Overt hyperthyroidism</u> (N = 75)	Slope (A)	0.002±0.003	0.003±0.007	0.41±0.02 †††
	Intercept (B)	-4.44±0.19	-4.40±0.16	-1.79±1.25
	Pearson's r	0.07	0.04	0.91
	P-value	0.56	0.72	<0.001

The FT3:FT4 ratio in 3,875 healthy euthyroid controls across 5 segments of the normal TSH reference range

TSH levels (mU/L)	n.	TSH (mU/L)	FT4 (pmol/L)	FT3 (pmol/L)	FT3/FT4 ratio
0.40–1.00	1306	0.7	14.2	4.47	0.31
	IQR range	(0.57–0.90)	(12.5–15.7)	(3.85–5.00)	(0.27–0.36)
1.01–1.50	878	1.3	13.9	4.34	0.31
	IQR range	(1.16–1.40)	(12.1–15.4)	(3.85–4.93)	(0.27–0.37)
1.51–2.00	625	1.79	13.8	4.47	0.31
	IQR range	(1.62–1.90)	(12.0–15.4)	(3.85–4.93)	(0.27–0.37)
2.01–2.50	402	2.26	13.4	4.47	0.32
	IQR range	(2.11–2.40)	(11.6–15.4)	(3.85–4.94)	(0.27–0.37)
2.51–4.00	664	3.1	12.9	4.47	0.33
	IQR range	(2.70–3.70)	(11.6–15.0)	(3.85–5.00)	(0.28–0.39)


Source: Gullo et al, 2011, PLoS ONE 6(8): e22552
doi:10.1371/journal.pone.0022552.g001

(From Lamichhane et al (Thyroid Hormones-Thyrotropin Interrelationships 2020) <https://www.biorxiv.org/content/10.1101/2020.06.26.173252v1>

(From Normal FT3:FT4 Thyroid Hormone Ratios in Large Populations – Thyroid Patients Canada <https://www.biorxiv.org/content/10.1101/2020.06.26.173252v1>

There is no one Thyroid assay that can ensure Euthyroidism. Recent work with Free Thyroid Assays show that the Ratio of Free T3 to Free T4 may be a more useful clinical parameter. The above figure indicates the distinct ratio differences in the major Thyroid Classifications, that Euthyroid and SC Hyperthyroid have similar ratio. The ratio is noted stable across \uparrow TSH in SC.

XXX. FreeT3 TRIAD PLUS FreeT4 ACTIONS




T3 and T4 have compartmentalized effects in the cell and varied onset:

- Nuclear/Mitochondrial Genomic
- Type 1,2 (T3, T4>T3) SLOW
- Cellular Non-Genomic
- Type 3 (T3,T4>T3) FAST
- Membrane Integrin Non-Genomic
- Type 4 (T4) FAST

XVIII. THYROID, THYROID EVERYWHERE A NOT A DROP TO DRINK

From *Optimal Thyroid Hormone Replacement* - Jonklaas
Endocr Rev. 2021 Sep 20;43(2):366–404. doi: 10.1210/endoev/bnab031
<https://pmc.ncbi.nlm.nih.gov/articles/PMC8905334/figure/F1/>
<https://pmc.ncbi.nlm.nih.gov/articles/PMC8905334/>



One issue with Thyroid metabolism is its ubiquity and compartmentalization. *“The clinical manifestations of hypothyroidism are diverse and potentially emanate from the effects of thyroid hormone deficiency in any organ system of the body. Both signs and symptoms exhibit a wide spectrum of severity, ranging from subtle to profound.”*

All cell metabolism appears to be modulated by Thyroid Hormones in Ratio FreeT3/FreeT4 balancing. There is a need to include other basic Hormones (Estradiol, Progesterone, Vitamin D, Vitamin A, Thyroxine, Triiodothyronine).